Literature DB >> 15721385

Long-circulating sterically stabilized liposomes in the treatment of infections.

Irma A J M Bakker-Woudenberg1, Raymond M Schiffelers, Gert Storm, Martin J Becker, Luke Guo.   

Abstract

The administration of antimicrobial agents encapsulated in long-circulating sterically stabilized liposomes results in a considerable enhancement of therapeutic efficacy compared with the agents in the free form. After liposomal encapsulation, the pharmacokinetics of the antimicrobial agents is significantly changed. An increase in circulation time and reduction in toxic side effects of the agents are observed. In contrast to other types of long-circulating liposomes, an important characteristic of these sterically stabilized liposomes is that their prolonged blood circulation time is, to a high degree, independent of liposome characteristics such as liposome particle size, charge and lipid composition (rigidity) of the bilayer, and lipid dose. This provides the opportunity to manipulate antibiotic release from these liposomes at the site of infection, which is important in view of the differences in pharmacodynamics of different antibiotics and can be done without compromising blood circulation time and degree of target localization of these liposomes. Depending on the liposome characteristics and the agent encapsulated, antibiotic delivery to the infected site is achieved, or the liposomes act as a micro-reservoir function for the antibiotic. In experimental models of localized or disseminated bacterial and fungal infections, the sterically stabilized liposomes have successfully been used to improve antibiotic treatment using representative agents of various classes of antibacterial agents such as the beta-lactams, the aminoglycosides, and the quinolones or the antifungal agent amphotericin B. Extensive biodistribution studies have been performed. Critical factors that contribute to liposome target localization in infected tissue have been elucidated. Liposome-related factors that were investigated were poly(ethylene glycol) density, particle size, bilayer fluidity, negative surface charge, and circulation kinetics. Host-related factors focused on the components of the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721385     DOI: 10.1016/S0076-6879(05)91014-8

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  12 in total

1.  Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.

Authors:  D Andes; N Safdar; K Marchillo; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Multiple lipid compartments slow vesicle contents release in lipases and serum.

Authors:  Cecile Boyer; Joseph A Zasadzinski
Journal:  ACS Nano       Date:  2007-10       Impact factor: 15.881

3.  PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin.

Authors:  Krishna Muppidi; Jeffrey Wang; Guru Betageri; Andrew S Pumerantz
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

4.  Development of an antifungal denture adhesive film for oral candidiasis utilizing hot melt extrusion technology.

Authors:  Jun-Bom Park; Suneela Prodduturi; Joe Morott; Vijay I Kulkarni; Melissa R Jacob; Shabana I Khan; Steven P Stodghill; Michael A Repka
Journal:  Expert Opin Drug Deliv       Date:  2014-08-29       Impact factor: 6.648

5.  Design and in situ characterization of lipid containers with enhanced drug retention.

Authors:  Benjamin Wong; Cecile Boyer; Christian Steinbeck; David Peters; Jason Schmidt; Ryan van Zanten; Bradley Chmelka; Joseph A Zasadzinski
Journal:  Adv Mater       Date:  2011-01-25       Impact factor: 30.849

Review 6.  Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases.

Authors:  Meredith A Mintzer; Eric L Dane; George A O'Toole; Mark W Grinstaff
Journal:  Mol Pharm       Date:  2011-12-13       Impact factor: 4.939

7.  Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes.

Authors:  Adam B Shapiro; Joseph Newman; Kosalaram Goteti; Marie-Eve Beaudoin; Rane Harrison; Sussie Hopkins; Nikunj Agrawal; Olga Rivin
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

8.  Development and stability studies of novel liposomal vancomycin formulations.

Authors:  Krishna Muppidi; Andrew S Pumerantz; Jeffrey Wang; Guru Betageri
Journal:  ISRN Pharm       Date:  2012-01-26

9.  The antimicrobial activity of free and immobilized poly (diallyldimethylammonium) chloride in nanoparticles of poly (methylmethacrylate).

Authors:  Luccas Missfeldt Sanches; Denise Freitas Siqueira Petri; Letícia Dias de Melo Carrasco; Ana Maria Carmona-Ribeiro
Journal:  J Nanobiotechnology       Date:  2015-09-24       Impact factor: 10.435

Review 10.  Theranostics Aspects of Various Nanoparticles in Veterinary Medicine.

Authors:  Ding-Ping Bai; Xin-Yu Lin; Yi-Fan Huang; Xi-Feng Zhang
Journal:  Int J Mol Sci       Date:  2018-10-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.